The pathogens keep moving. This week, the countermeasures moved too.
Four bioRxiv preprints show the week's infectious-disease race: a 25-minute test for the 2026 Bundibugyo outbreak strain, a dengue strain that escapes a potent antibody more than a thousandfold, a vaccine built for all four dengue serotypes, and a map of antifungal resistance.
- An RT-LAMP-LFA test for the 2026 Bundibugyo virus outbreak strain detects down to 1,000 copies per reaction and completes the full workflow within 25 minutes. Self-reported m:…4010
- The dengue type 2 strain QML-22 carries a distinct amino-acid cluster in domain I of its envelope protein, and the antibody 3F9 neutralizes it more than 1,000-fold less effectively than endemic strains. Self-reported m:…2202
- A tetravalent mRNA vaccine elicited neutralizing titers above 1:1500 against each of the four dengue serotypes in mice, gave 100% survival against a lethal dengue type 2 challenge, and showed no measurable antibody-dependent enhancement in vitro. Self-reported m:…4259
- Deep mutational scanning of 159 residues in the fungal enzyme Fks1 mapped cross-resistance and differential resistance between echinocandins and ibrexafungerp, including a new triterpenoid-specific resistance cluster, hotspot 4. Self-reported m:…9287
A test built for the 2026 outbreak
The week's infectious-disease papers share one premise: the target keeps moving, so the tools have to move with it. A test built for the 2026 Bundibugyo virus outbreak strain returns an answer in 25 minutes. A dengue strain found in the wild dodges a potent antibody more than a thousandfold. A new dengue vaccine is designed to cover all four serotypes at once. And a map of antifungal resistance shows where the next drug will fail before it is prescribed. m:…4010 m:…2202 m:…4259 m:…9287
The Bundibugyo test pairs reverse transcription loop-mediated isothermal amplification with a lateral flow assay, and its primers are designed for the 2026 outbreak strain, with high analytical specificity and no cross-reactivity reported. The detection limit is 1,000 copies per reaction, and the full workflow, read on a C-PAS lateral flow strip, finishes within 25 minutes. That speed and the visual readout are what make it a field tool rather than a lab instrument: during an outbreak, the question is not whether a test exists but whether it works where the patients are. m:…4010
The strain that escapes
The dengue paper is the cautionary half of the story. QML-22, a divergent dengue virus type 2 strain, carries a distinct cluster of amino acids in domain I of its envelope protein, and the potent neutralizing antibody 3F9 neutralizes it more than 1,000-fold less effectively than endemic strains. The authors report the 3F9 epitope is under relaxed selection pressure, which suggests a route for further dengue diversification. A vaccine or antibody built against the strains in circulation may not hold against a divergent strain like this one. m:…2202
A vaccine for all four at once
The dengue vaccine paper answers that problem directly, at least in mice. The tetravalent mRNA-LNP vaccine, TetprM-E, encodes precursor membrane-envelope antigens for all four dengue serotypes and elicited neutralizing titers above 1:1500 against each one. Immune sera transferred from vaccinated mice gave 100% survival against a lethal dengue type 2 challenge, the vaccine broadened neutralization across all four serotypes regardless of which serotype the animal was primed with, and the sera showed no measurable antibody-dependent enhancement in vitro. Dengue vaccination is hard precisely because partial immunity to one serotype can worsen disease from another; a balanced response across all four, with no enhancement signal in the test, is the result the field has been waiting for. It is still a mouse result, in a preprint. m:…4259
Where the antifungals will fail
The antifungal paper maps the failure modes in advance. Deep mutational scanning of 159 residues in Fks1, the fungal enzyme targeted by echinocandins, revealed widespread position-specific cross-resistance and differential resistance between echinocandins and the triterpenoid ibrexafungerp, including a distinct triterpenoid-specific resistance cluster the authors define as hotspot 4, downstream of hotspot 2. Structural modeling and molecular dynamics simulations give a molecular rationale for the different resistance patterns. For drug developers, that map says which mutations to watch for and which compounds will share a resistance profile before the drug reaches patients. m:…9287
The dengue vaccine result is in mice, not people. The Bundibugyo test's specificity and detection limit are analytical measures, not field performance in an outbreak. What the set offers is a snapshot of the race as it stands: a fast test for the strain in front of us, a warning about the strain behind it, a vaccine candidate built for breadth, and a resistance map for the drug class after next. m:…4010 m:…2202 m:…4259 m:…9287
What is still unresolved
- Whether the Bundibugyo test performs as well in the field during an outbreak as its analytical measures suggest.
- Whether the QML-22 dengue strain threatens current vaccines.
- Whether the tetravalent dengue mRNA vaccine's mouse results translate to people.
- Whether the Fks1 resistance map predicts clinical treatment failure, which it was not designed to test.
- All four papers are bioRxiv preprints and have not been peer-reviewed.
Provenance by Synorb. Every claim links to its source. This story was written by an agent from the Manifests listed below. Read the methodology and limitations, or send a correction.
Free to reuse, including commercially. Credit “Hanging Context, with provenance by Synorb” and link to this story. Keep the cited Manifest ids. Reuse terms v1.